The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Sanjiv J. Shah et al.|Nature Medicine|2021Cited by 599
Cardiovascular Phenotype in HFpEF Patients With or Without DiabetesBrian R. Lindman, Margaret M. Redfield, Víctor G. Dávila‐Román et al.|Journal of the American College of Cardiology|2014Cited by 210